Gadodiamide

Gadodiamide

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	i.v.
ATC code	V08CA03 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	negligible
Metabolism	not metabolized
Biological half-life	77.8 minutes
Excretion	renal
Identifiers
IUPAC name gadolinium(III) 5,8-bis(carboxylatomethyl)-2-[2-(methylamino)-2-oxoethyl]-10-oxo-2,5,8,11-tetraazadodecane-1-carboxylate hydrate
Synonyms	2-[bis[2-(carboxylatomethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetate; gadolinium(+3) cation
CAS Number	131410-48-5 N
PubChem CID	153921
DrugBank	DB00225 Y
ChemSpider	135661 Y
UNII	84F6U3J2R6
KEGG	D01645 Y
ChEBI	CHEBI:37333 Y
ChEMBL	CHEMBL1200346 N
Chemical and physical data
Formula	C16H28GdN5O9
Molar mass	591.672g/mol
3D model (Jmol)	Interactive image
SMILES [Gd+3].[O-]C(=O)CN(CC(=O)NC)CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O
InChI InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3 Y Key:HZHFFEYYPYZMNU-UHFFFAOYSA-K Y
NY (what is this?)

Gadodiamide is a gadolinium-based MRI contrast agent, used in MR imaging procedures to assist in the visualization of blood vessels. It is commonly marketed under the trade name Omniscan.

A 2015 study found trace amounts of Gadolinium deposited in the brain tissue of patients that had received Gadodiamide.

Gadodiamide is a contrast medium for cranial and spinal magnetic resonance imaging (MRI) and for general MRI of the body after intravenous administration. The product provides contrast enhancement and facilitates visualisation of abnormal structures or lesions in various parts of the body including the central nervous system (CNS). It does not cross an intact blood brain barrier but might give enhancement in pathological conditions.

In February 2008, Danish media stated that gadolinium-based agents may be associated with a toxic reaction known as nephrogenic systemic fibrosis (NSF) in some patients with severe kidney problems.

Some articles suggested that over 60 persons examined with Omniscan had either died or had been severely disabled as a result of the use of the product. However, a recent report by the Danish Medicines Agency stated that there were 35 cases of NSF reported after use of Omniscan and that 33 of these had been reported from a single centre in Copenhagen. However, already in 2001, a case of renal toxicity and pancreatitis associated with Omniscan use for arteriography had been reported. In their paper, the authors also referred to two other previous case reports (1998 and 1999) of acute renal failure after gadoteridol (Prohance) intraarterially and acute pancreatitis after intravenous gadolinium-diethylene triamine pentaacetic acid (Magnevist). A case of cardiac arrest has also been reported. Gadopentetate dimeglumine (Magnevist) was administered during an MR study of the head, and from the rapid onset of signs and symptoms and subsequent cardiovascular arrest, a cause-and-effect relationship was suggested. In the interest of public health, it seems important that not only renal disease should be considered a factor when decisions about the use of this kind of MRI contrast is taken.